None
Conditions
Interventions
Treatment group :Participant will take oral taurine (3g/day) or identical looking placebo over a 6-month period. All participants will need to complete questionnaires i.e. Center for Epidemiologic St
Placebo group :Participant will take identical looking placebo orally over a 6-month period. All participants will need to complete questionnaires i.e. Center for Epidemiologic Studies Depression Sca
Sponsors
The Chinese University of Hong Kong
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Healthcare related workers who can read and understand English or Chinese translated version of the study questionnaires will be invited to participate including doctors, nurses, physiotherapists, dietitians, or research-related workers at the New Territories East Cluster Hospitals
Exclusion criteria
Exclusion criteria: (a)Are taking taurine prior to enrolment, (b) Have chronic renal disease (eGFR<30ml/min: as taurine can accumulate in renal failure) (c) Insulin-dependent diabetes mellitus (d) A bleeding disorder (e.g. platelet count < 100x10^9/L or treated with dual antiplatelet agents: as taurine has potential antiplatelet activity in vitro) (e) Received active chemo/immunotherapy < 30 days before enrolment or likely to receive such treatment during the study (f) Pregnant or planning to become pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c;Methyglyoxal level;Plasma taurine level; | — |
Secondary
| Measure | Time frame |
|---|---|
| LDL and triglyceride levels;PhenoAge;Body weight;IPAQ;Blood pressure;Center for Epidemiologic Studies Depression Scale;AGEs index; | — |
Countries
China
Contacts
Public ContactKwok Ming HO
Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong
Outcome results
None listed